New hope for mysterious cancers: immune therapy trial shows promise
NCT ID NCT03752333
Summary
This study tested whether the immunotherapy drug pembrolizumab could help control cancer of unknown primary, where doctors can't identify where the cancer started. The trial included 35 patients in two groups: those who had already tried chemotherapy and those receiving it as their first treatment. Researchers measured whether the drug could shrink tumors, extend survival, and improve quality of life compared to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gastrointestinal Units - The Royal Marsden Hospitals at Sutton and London
Sutton, Surrey, United Kingdom
-
Guy's Cancer Centre
London, United Kingdom
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.